原文标题：
Teladoc stock plunges more than 30% after earnings outlook slashed, massive
impairment charge
原文连结：https://news.futunn.com/hk/post/14972209
发布时间：2022/04/28 0533
原文内容：
Teladoc stock plunges more than 30% after earnings outlook slashed, massive
impairment charge
Teladoc股价暴跌逾30%，此前收益预期大幅下调，出现钜额减值费用
Shares head toward lowest levels in more than four years as online-medicine
company wipes away more than $6.5 billion in goodwill
随着在线医药公司抹去超过65亿美元的商誉，股价跌至四年多来的最低水平
Shares of Teladoc Health Inc. were slammed in after-hours trading Wednesday,
after the telemedicine company took an impairment charge of more than $6.5
billion and slashed its full-year outlook.
Teladoc Health Inc.的股价周三在盘后交易中遭受重创，此前这家远程医疗公司计入了
超过65亿美元的减值费用，并大幅下调了全年预期。
Teladoc(TDOC) executives now expect $2.4 billion to $2.5 billion in revenue
for the full year, along with $240 million to $265 million in adjusted
earnings before interest, taxes, depreciation, and amortization (Ebitda).
Their prior forecast called for $2.55 billion to $2.65 billion in revenue and
$330 million to $355 million in adjusted Ebitda.
Teladoc的高管目前预计，该公司全年营收为24亿至25亿美元，调整后的息税折旧及摊销
前利润(EBITDA)为2.4亿至2.65亿美元。他们之前的预测是收入25.5亿至26.5亿美元，调
整后的EBITDA为3.3亿至3.55亿美元。
Shares were off more than 30% in after-hours trading, falling lower than $38
after closing with a 3.1% decline at $55.99. Shares haven't traded for lower
than $38 in a regular session since March 2018.
股价在盘后交易中下跌超过30%，跌破38美元，收盘时下跌3.1%，至55.99美元。自2018年
3月以来，股票在常规交易时段的交易价格从未低于38美元。
Teladoc's new forecast reflects trends that executives are seeing in the
market for direct-to-consumer mental-health and chronic-condition services,
such as higher advertising costs in the mental-health market that are causing
lower-than-anticipated yields on its marketing spending. It also cited an
"elongated sales cycle as employers and health plans evaluate their long-term
strategies" in the chronic-condition market.
Teladoc的新预测反映了高管们在直接面向消费者的心理健康和慢性病服务市场上看到的
趋势，比如心理健康市场的广告成本上升，导致其营销支出的收益率低于预期。报告还指
出，在慢性病市场，“随着雇主和健康计划评估他们的长期战略，销售周期延长”。
"Despite the revision to our 2022 outlook, we are confident in our strategy,
along with our breadth and depth of capabilities," Chief Executive Jason
Gorevic said in a release.
首席执行官杰森·戈雷维奇在一份新闻稿中表示：“尽管我们对2022年的展望进行了修订
，但我们对我们的战略以及我们的能力的广度和深度充满信心。”
Gorevic shared on Teladoc's earnings call that about three-quarters of the
cut to the revenue outlook was related to the company's BetterHelp
online-counseling product, while the rest reflected new top-line expectations
for the chronic-care business.
戈雷维奇在Teladoc的财报电话会议上分享到，收入预期下调的四分之三与该公司的
BetterHelp在线咨询产品有关，其余的反映了对慢性护理业务的新的营收预期。
For the first quarter, Teladoc generated a net loss of $6.67 billion, or
$41.58 a share, whereas it recorded a loss of $200 million, or $1.31 a share,
in the year-prior period. Teladoc's loss in the most recent quarter largely
reflected a $6.6 billion impairment charge related to goodwill.
第一季度，Teladoc净亏损66.7亿美元，合每股41.58美元，而去年同期亏损2亿美元，合
每股1.31美元。Teladoc最近一个季度的亏损在很大程度上反映了与商誉相关的66亿美元
减值费用。
Teladoc executives did not disclose much about the goodwill impairment charge
in Wednesday's news release, but roughly $12.8 billion of the $14.5 billion
in goodwill on Teladoc's books stemmed from the $18.5 billion acquisition of
Livongo in 2020, according to the company's filings with the Securities and
Exchange Commission.
Teladoc的高管在周三的新闻稿中没有透露太多有关商誉减值费用的信息，但根据该公司
提交给美国证券交易委员会(Securities And Exchange Commission)的文件，Teladoc账
面上的145亿美元商誉中，约有128亿美元来自2020年以185亿美元收购Livongo的交易。
"The goodwill impairment was triggered by the sustained decline in Teladoc
Health share price with a valuation and size of the impairment charge driven
by a combination of recent market-based factors such as an increased discount
rate and the decreased market multiples for a relevant peer group of
high-growth digital health-care companies, as well as updates to our
forecasted cash flows consistent with the revised guidance disclosed today,"
Chief Financial Officer Mala Murthy said in the most substantive statement
executives gave about the $6.6 billion charge during a conference call
Wednesday afternoon.
Teladoc Health的首席财务长玛拉·穆尔西在周三下午的电话会议上说，商誉减值是由
Teladoc Health股价的持续下跌引发的，减值费用的估值和规模是由最近的基于市场的因
素共同推动的，比如贴现率增加，相关的高增长数字医疗保健公司的市盈率下降，以及我
们预测的现金流更新与今天披露的修订指引一致，这是高管们在周三下午的电话会议上就
66亿美元的费用发表的最实质性的声明。
The company's revenue rose to $565.4 million from $453.7 million, while
analysts tracked by FactSet had been anticipating $569 million.
该公司的收入从4.537亿美元增至5.654亿美元，而FactSet追踪的分析师此前预计为5.69
亿美元。
For the second quarter, Teladoc projects adjusted Ebitda of $39 million to
$49 million on revenue of $580 million to $600 million, while the FactSet
consensus is for $71 million in adjusted Ebitda and $615 million in revenue.
对于第二季度，Teladoc预计调整后的EBITDA为3900万美元至4900万美元，收入为5.8亿美
元至6亿美元，而FactSet的共识是调整后的EBITDA为7100万美元，收入为6.15亿美元。
Teladoc shares had already declined 39% so far this year and more than 70% in
the past 12 months, as the S&P 500 index declined 12.4% and 0.3% respectively.
今年到目前为止，Teladoc的股价已经下跌了39%，在过去12个月里下跌了70%以上，标准
普尔500指数分别下跌了12.4%和0.3%。
心得/评论： ※必需填写满30字，无意义者板规处分
版友提到这股,想说在崩崩崩就帮忙搬运一下,没什么研究.只知道是Wood爱股..
我查了ARK的交易纪录....
该说是不意外吗?
https://i.imgur.com/pGLWGd0.png
April 25, 2022 BUY 9.808k 0.019% ARKG
April 25, 2022 BUY 4.717k 0.0143% ARKW
April 25, 2022 BUY 28.191k 0.0171% ARKK
April 25, 2022 BUY 2.224k 0.011% ARKF
April 26, 2022 BUY 5.015k 0.0247% ARKF
April 26, 2022 BUY 10.597k 0.0314% ARKW
April 26, 2022 BUY 22.072k 0.0423% ARKG
April 26, 2022 BUY 63.879k 0.0379% ARKK